1. Home
  2. NRIX vs CGBD Comparison

NRIX vs CGBD Comparison

Compare NRIX & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • CGBD
  • Stock Information
  • Founded
  • NRIX 2009
  • CGBD 2012
  • Country
  • NRIX United States
  • CGBD United States
  • Employees
  • NRIX N/A
  • CGBD N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • CGBD Finance: Consumer Services
  • Sector
  • NRIX Health Care
  • CGBD Finance
  • Exchange
  • NRIX Nasdaq
  • CGBD Nasdaq
  • Market Cap
  • NRIX 750.4M
  • CGBD 881.4M
  • IPO Year
  • NRIX 2020
  • CGBD 2017
  • Fundamental
  • Price
  • NRIX $12.78
  • CGBD $12.56
  • Analyst Decision
  • NRIX Strong Buy
  • CGBD Hold
  • Analyst Count
  • NRIX 14
  • CGBD 5
  • Target Price
  • NRIX $26.29
  • CGBD $14.25
  • AVG Volume (30 Days)
  • NRIX 1.7M
  • CGBD 625.3K
  • Earning Date
  • NRIX 10-09-2025
  • CGBD 11-04-2025
  • Dividend Yield
  • NRIX N/A
  • CGBD 12.37%
  • EPS Growth
  • NRIX N/A
  • CGBD N/A
  • EPS
  • NRIX N/A
  • CGBD 1.14
  • Revenue
  • NRIX $83,687,000.00
  • CGBD $234,464,000.00
  • Revenue This Year
  • NRIX $58.48
  • CGBD $15.09
  • Revenue Next Year
  • NRIX N/A
  • CGBD $5.69
  • P/E Ratio
  • NRIX N/A
  • CGBD $11.18
  • Revenue Growth
  • NRIX 48.32
  • CGBD N/A
  • 52 Week Low
  • NRIX $8.18
  • CGBD $11.65
  • 52 Week High
  • NRIX $29.56
  • CGBD $18.64
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 64.49
  • CGBD 51.46
  • Support Level
  • NRIX $11.37
  • CGBD $12.68
  • Resistance Level
  • NRIX $12.45
  • CGBD $13.05
  • Average True Range (ATR)
  • NRIX 0.75
  • CGBD 0.26
  • MACD
  • NRIX 0.20
  • CGBD 0.11
  • Stochastic Oscillator
  • NRIX 84.06
  • CGBD 75.00

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

Share on Social Networks: